Tier 3 — preclinical

Absorption, anti-inflammatory, antioxidant, and cardioprotective impacts of a novel fasting mimetic containing spermidine, nicotinamide, palmitoylethanolamide, and oleoylethanolamide: A pilot dose-escalation study in healthy young adult men

Christopher H Rhodes, Brian V Hong, Xinyu Tang, Cheng-Yu Weng, Jea Woo Kang, Joanne K Agus, Carlito B Lebrilla, Angela M Zivkovic

Nutrition Research 2024 132:125-135

Bibliography

PubMed: PMID 39549554
DOI: 10.1016/j.nutres.2024.10.006
Trial registry: View on ClinicalTrials.gov Registered trial — results not yet published in a peer-reviewed journal.

Study snapshot

Design	Randomized pilot dose-escalation feeding study
Model	Healthy young adult men
Sample	5
Intervention	Control or low, medium and high doses of a formulation containing spermidine, nicotinamide, PEA and OEA after a standardized breakfast
Duration	Acute single-dose sessions with blood sampling over 4 hours after supplementation (through 6 hours postprandial)
Endpoints	Plasma spermidine; Metabolite absorption; TNF-alpha response; Reactive oxygen species; Cholesterol efflux capacity

What the study showed, in plain terms

In five men, a multi-ingredient fasting-mimetic formulation was tested across escalating doses. The study provides preliminary absorption and ex-vivo functional data but cannot isolate spermidine's contribution.

Key findings

Plasma spermidine did not show a simple dose-related rise; the combined supplement altered other components and ex-vivo inflammatory/oxidative measures. This is formulation research, not direct evidence for standalone spermidine efficacy.

What this study can and cannot tell us

Only five participants, acute time course, multi-ingredient formulation and surrogate/ex-vivo endpoints. The findings are exploratory.

Editorial review

Reviewed by the Biohack Blueprint research team

Khaled Mahmoud